EMTRIVA 200 mg CAPSULES
How to use EMTRIVA 200 mg CAPSULES
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Emtriva 200 mg Hard Capsules
Emtricitabine
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Emtriva and what is it used for
- What you need to know before you take Emtriva
- How to take Emtriva
- Possible side effects
- Storage of Emtriva
- Contents of the pack and further information
1. What is Emtriva and what is it used for
Emtriva is a medicine used to treat human immunodeficiency virus (HIV) infectionin adults, children, and infants from 4 months of age and older .Emtriva 200 mg hard capsules is only suitable for patients who weigh at least 33 kg. Emtriva oral solution is available for people who have difficulty swallowing Emtriva hard capsules.
Emtriva contains the active substanceemtricitabine.This active substance is an antiretroviralmedicine used to treat HIV infection. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI)that works by interfering with the normal working of an enzyme (reverse transcriptase) that is essential for the HIV virus to reproduce. Emtriva may decrease the amount of HIV in your blood (viral load). This may also help increase the number of CD4 cells called T cells. Emtriva must always be used in combination with other medicines to treat HIV infection.
While taking this medicine you can still pass on HIV to others, even if effective antiviral treatment has reduced the virus to undetectable levels. Ask your doctor about the precautions needed to avoid infecting others.
This medicine does not cure HIV infection.When taking Emtriva, you may still develop infections or other illnesses associated with HIV infection.
2. What you need to know before you take Emtriva
Do not take Emtriva
- If you are allergicto emtricitabine or any of the other ingredients of this medicine (listed in section 6).
If this happens, contact your doctor immediately.
Warnings and precautions
- If you have had kidney diseaseor if blood tests have shown kidney problems, tell your doctor. Before starting treatment, your doctor may ask you to have blood tests to check your kidney function and may advise you to take the capsules less frequently or prescribe Emtriva oral solution. Your doctor may also ask you to have blood tests during treatment to monitor your kidneys.
- If you are over 65 years of age, tell your doctor.Emtriva has not been studied in patients over 65 years of age. If you are over this age and have been prescribed Emtriva, your doctor will monitor you closely.
- Talk to your doctor if you have a history of liver disease, including hepatitis.Patients with liver disease, including chronic hepatitis B or C, treated with antiretrovirals, have a greater risk of severe liver complications that can be life-threatening. If you have a hepatitis B infection, your doctor will carefully consider the best treatment for you. If you have a history of liver disease or chronic hepatitis B infection, your doctor may perform blood tests to closely monitor liver function.
- Infections.If you have advanced HIV infection (AIDS) and another infection, you may develop inflammation or worsening of infection symptoms when you start treatment with Emtriva. These may be signs that your immune system is improving and fighting the infection. If you notice signs of inflammation or infection soon after starting Emtriva, contact your doctor immediately.
In addition to opportunistic infections, autoimmune disorders (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you have started taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after starting treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness starting in the hands and feet and moving up towards the trunk of the body, palpitations, tremors, or hyperactivity, inform your doctor immediately to receive the necessary treatment.
- Bone problems.Some patients receiving combination antiretroviral therapy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). Among the many risk factors for developing this disease are the duration of combination antiretroviral therapy, the use of corticosteroids, alcohol consumption, severe immunosuppression, and high body mass index. The symptoms of osteonecrosis are joint stiffness, pain, and discomfort (especially in the hip, knee, and shoulder) and difficulty moving. If you notice any of these symptoms, inform your doctor.
Children and adolescents
Do not give Emtriva to infantsunder 4 months of age.
Taking Emtriva with other medicines
Do not take Emtrivaif you are already taking other medicines that contain emtricitabine or lamivudine, which are also used to treat HIV infection, unless your doctor tells you to.
Tell your doctor or pharmacistif you are taking, have recently taken, or might take any other medicines.
Do not stop your treatment without consulting your doctor.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
If you have been taking Emtriva during your pregnancy, your doctor may ask you to have regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit of protection against HIV was greater than the risk of side effects.
- Do not breastfeed your child while taking Emtriva.This is because the active substance of this medicine passes into breast milk. It is known that the virus can pass to the baby through breast milk.
Driving and using machines
Emtriva may cause dizziness. If you feel dizzy while taking Emtriva, do not driveor operate tools or machines.
3. How to take Emtriva
- Always take this medicine exactly as your doctor has told you.If you are not sure, check with your doctor or pharmacist.
The recommended dose is:
- Adults: One 200 mg hard capsule, once daily, with or without food.Swallow the hard capsules with a glass of water.
- Children and adolescents up to 18 years of agewho weigh at least 33 kg and can swallow the hard capsules: one 200 mg hard capsule, once daily, with or without food.
For infants from 4 months, children, and patients who cannot swallow the hard capsules, and patients with kidney problems, Emtriva is available in liquid form (oral solution). Inform your doctor if you have difficulty swallowing the capsules.
- Always take the dose recommended by your doctor.This is to ensure that your medicine is completely effective and to reduce the risk of developing resistance to treatment. Do not change the dose unless your doctor tells you to.
- If you have kidney problems,your doctor may advise you to take Emtriva less frequently.
- Your doctor will prescribe Emtriva with other antiretroviral medicines.Read the package leaflets of the other antiretrovirals to find out how to take these medicines.
If you take more Emtriva than you should
If you accidentally take too many Emtriva hard capsules, contact your doctor or go to the nearest emergency department. Take the package with you so that you can easily describe what you have taken.
If you forget to take Emtriva
It is important that you do not miss a dose of Emtriva.
If you forget a dose of Emtriva within 12 hours of when you normally take it,take it as soon as you can, and then take your next dose at the usual time.
If it is almost time for your next dose (less than 12 hours),do not take the missed dose. Wait and take the next dose at the usual time. Do not take a double dose to make up for the missed capsule.
If you feel like vomiting
If it has been less than one hour since you took Emtriva,take another capsule. You do not need to take another capsule if you vomit after one hour of taking Emtriva.
If you stop taking Emtriva
- Do not stop taking Emtriva without consulting your doctor.Stopping treatment with Emtriva may reduce the effectiveness of the HIV therapy recommended by your doctor. Talk to your doctor before stopping, especially if you are experiencing any side effects or have another illness. Contact your doctor again before restarting Emtriva.
- If you have HIV and hepatitis B infection,it is especially important not to stop your treatment with Emtriva without first talking to your doctor. Some patients have had blood tests or symptoms indicating that their hepatitis had worsened after stopping Emtriva. You may need to have blood tests for several months after stopping treatment. In patients with advanced liver disease or cirrhosis, it is not recommended to stop treatment as this may lead to worsening of hepatitis.
Talk to your doctor immediately about new or unusual symptoms after stopping your treatment, especially symptoms that you associate with hepatitis B virus infection.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
During HIV treatment, there may be an increase in weight and levels of glucose and lipids in the blood. This may be partly related to the recovery of health and lifestyle, and in the case of lipids in the blood, sometimes to HIV medicines themselves. Your doctor will monitor these changes.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor about any of the following side effects:
Very common side effects
The following side effects are very common(may affect more than 10 in every 100 patients):
- headache, diarrhea, nausea
- muscle pain and weakness (if creatine kinase levels increase in the blood)
Other possible side effects
The following side effects are common(may affect up to 10 in every 100 patients):
- dizziness, weakness, difficulty sleeping, nightmares
- vomiting, digestive problems with discomfort after meals, stomach pain
- rash (including red spots or patches sometimes with blisters and swelling of the skin), which may be allergic reactions, itching, changes in skin color such as darkening of the skin in patches
- pain
Blood tests may also show:
- low white blood cell count (a reduced number of white blood cells can make you more prone to infections)
- increased triglycerides (fatty acids), bilirubin, or sugar in the blood
- liver or pancreas problems
The following side effects are uncommon(may affect up to 1 in every 100 patients):
- anemia (low red blood cell count)
- swelling of the face, lips, tongue, or throat
Other possible effects
Children who received emtricitabine also very commonlyexperienced changes in skin colorincluding darkening of the skin in patches, and commonlyexperienced anemia(low red blood cell count). If red blood cell production decreases, the child may experience symptoms of tiredness or shortness of breath.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Annex V. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Emtriva
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, blister, and packaging after “EXP”. The expiry date is the last day of the month stated.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Container Contents and Additional Information
Composition of Emtriva
- The active ingredient isemtricitabine. Each hard capsule of Emtriva contains 200 mg of emtricitabine.
- The other ingredients are:
Capsule content: Microcrystalline cellulose (E460), Crospovidone, Magnesium stearate (E572), Povidone (E1201)
Capsule shell: Gelatin, Indigotine (E132), Titanium dioxide (E171)
Printing ink with: Black iron oxide (E172), Shellac (E904)
Appearance of the Product and Container Contents
The hard capsule of Emtriva has a white opaque body with a pale blue opaque cap. Each capsule is marked with "200 mg" on the cap and "GILEAD" and the Gilead logo on the body, printed with black ink. Emtriva is available in bottles or blisters of 30 capsules.
Emtriva is also available as an oral solution for children and infants from 4 months or older, patients who have difficulty swallowing, and patients with kidney problems. There is a different leaflet for Emtriva 10 mg/ml oral solution.
Marketing Authorization Holder
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Manufacturer
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
You can request more information about this medicinal product by contacting the local representative of the marketing authorization holder:
Belgium Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 | Lithuania Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
Bulgaria Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Luxembourg Gilead Sciences Belgium SPRL-BVBA Tel: + 32 (0) 24 01 35 50 |
Czech Republic Gilead Sciences s.r.o. Tel: + 420 910 871 986 | Hungary Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Denmark Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 | Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Germany Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0 | Netherlands Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 98 |
Estonia Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | Norway Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Greece Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Austria Gilead Sciences GesmbH Tel: + 43 1 260 830 |
Spain Gilead Sciences, S.L. Tel: + 34 91 378 98 30 | Poland Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 |
France Gilead Sciences Tel: + 33 (0) 1 46 09 41 00 | Portugal Gilead Sciences, Lda. Tel: + 351 21 7928790 |
Croatia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 | Romania Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 999 | Slovenia Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1888 |
Iceland Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 | Slovakia Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 210 |
Italy Gilead Sciences S.r.l. Tel: + 39 02 439201 | Finland Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Cyprus Gilead Sciences Ελλάς Μ.ΕΠΕ. Tel: + 30 210 8930 100 | Sweden Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1849 |
Latvia Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8702 | United Kingdom Gilead Sciences Ltd. Tel: + 44 (0) 8000 113 700 |
Date of Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu.
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to EMTRIVA 200 mg CAPSULESDosage form: ORAL SOLUTION/SUSPENSION, 10 mgActive substance: emtricitabineManufacturer: Gilead Sciences Ireland Unlimited CompanyPrescription requiredDosage form: TABLET, 300 mgActive substance: abacavirManufacturer: Tarbis Farma S.L.Prescription requiredDosage form: TABLET, 300 mgActive substance: abacavirManufacturer: Zentiva K.S.Prescription required
Online doctors for EMTRIVA 200 mg CAPSULES
Discuss questions about EMTRIVA 200 mg CAPSULES, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions
